Orphan drug development is a rapidly expanding field. Nevertheless, clinical trials for rare diseases can present inherent challenges. Optimal study design and partnerships between academia and industry are therefore required for the successful development, delivery and clinical approval of effective therapies in this group of disorders.
- Chiara Pizzamiglio
- Hilary J. Vernon
- Robert D. S. Pitceathly
